1,572 results on '"Cappellini,Maria Domenica"'
Search Results
52. Clinical Complications and Their Management
53. Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
54. Dysregulation of Iron Metabolism-Linked Genes at Myocardial Tissue and Cell Levels in Dilated Cardiomyopathy
55. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
56. Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy-a Delphi consensus
57. When diagnostics meets translational research: detection of hemoglobin fractions in cellular lysates from in vitro erythroid cultures by Capillarys 2 Flex Piercing analyzer (Sebia)
58. Less ‘reds’ more ‘blues’: hemoglobin level and depression in non-transfusion-dependent thalassemia
59. Role of Non-Transferrin-Bound Iron in the pathogenesis of cardiotoxicity in patients with ST-elevation myocardial infarction assessed by Cardiac Magnetic Resonance Imaging
60. Current challenges in the management of patients with sickle cell disease – A report of the Italian experience
61. Luspatercept for transfusion-dependent β-thalassemia: time to get real
62. Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications
63. Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia
64. Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study
65. Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β-Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis
66. Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm
67. A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial
68. Ferric Carboxymaltose for Long-Term Correction of Iron Deficiency Anemia in the Emergency Department
69. Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial
70. Clinical Burden of β-Thalassemia: Findings from a Multinational Medical Record Abstraction Study
71. Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
72. Magnitude of cumulative iron overload correlates with the severity of anemia in untreated non-transfusion-dependent β-thalassemia
73. Emergent treatments for β-thalassemia and orphan drug legislations
74. Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients
75. Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure
76. Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population
77. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study
78. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
79. Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia
80. Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
81. The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID‐19: The IRONCOVID study
82. Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from three decades of follow-up in a high-income setting
83. Validity of β-d-glucosidase activity measured in dried blood samples for detection of potential Gaucher disease patients
84. Key terms and definitions in acute porphyrias: Results of an international Delphi consensus led by the European porphyria network.
85. Inhibition of FGF23 is a therapeutic strategy to target hematopoietic stem cell niche defects in β-thalassemia.
86. Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins
87. Hyponatremia: a challenge for internists
88. Efficacy and safety of givosiran in patients with acute hepatic porphyria: 36-month results of the phase 3 ENVISION randomised clinical trial
89. Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective
90. Redox Balance in β-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship
91. An open‐label, multicenter, efficacy and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia ( THETIS ): 5‐year results
92. 385: EFFICACY AND SAFETY OF GIVOSIRAN IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA: 36-MONTH RESULTS OF THE PHASE 3 ENVISION RANDOMIZED CLINICAL TRIAL
93. Evaluation of the 5 mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia
94. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia
95. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management
96. Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor
97. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review
98. One‐year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation
99. Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
100. Pulmonary dysfunction in thalassaemia major: is there any relationship with body iron stores?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.